- Risk-sharing alliance on tailor-made phenotypic models for IBD and HBV
- Upfront payment and milestone payments for MIMETAS
- Access to know-how on novel disease models and assays for Roche
- Option to exclusively license of disease models and assays for Roche
LEIDEN, The Netherlands, July 06, 2021 / B3C newswire / -- MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). Under the terms of the agreement, MIMETAS is eligible to receive an upfront payment and milestone payments from Roche.
MIMETAS will be responsible for developing tissue-based disease models and assays in the OrganoPlate, its proprietary organ-on-chip platform that increases predictability of biomarkers and reduces animal use in scientific testing. Roche will gain access to technology, disease models, and scientific results. Roche will also receive an option to exclusively license specific disease models and assays for use in drug discovery.
"This exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform our drug discovery process," said James Sabry, Global Head, Roche Pharma Partnering.
"The collaboration with Roche leverages our ongoing focus on developing predictive, phenotypic models, preceded by numerous successful projects over the last eight years," said Jos Joore, CEO of MIMETAS. "We will leverage our disease modeling expertise in our world-leading OrganoPlate platform to gain novel insights in IBD and HBV. Working together with the outstanding Roche team, we hope to make a difference in the lives of patients."
For high resolution please click the image.
About MIMETAS
MIMETAS (Leiden, The Netherlands) is a global leader in disease modeling using organ-on-a-chip technologies. Its proprietary OrganoPlate® platform enables the development and high-throughput screening of physiologically relevant disease models. The company offers its technology and know-how in therapy co-development projects, services, and off-the-shelf products. MIMETAS works with leading pharmaceutical and biotech companies worldwide to develop novel therapies against unsolved diseases. MIMETAS was founded in 2013 in Leiden, the Netherlands, and has grown to a multinational company with operations in Asia, Europe, and the USA.
Contact
MIMETAS BV
Jos Joore, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
+31 85 888 3161
Keywords: Humans; Models, Biological; Biological Assay; High-Throughput Screening Assays; Research; Laboratories; Lab-On-A-Chip Devices; Hepatitis B virus; Drug Discovery; Drug Development;Inflammatory Bowel Diseases; Biomarkers; Technology; Hepatitis B; Biotechnology; Netherlands
Published by B3C newswire